Evidence map›Paper›PMID 42657605›Full record

ArticleAdvanced healthcare materials2026

Charting Morphotoxicity With Complementary Embryo Models.

Dorian G Luijkx, Pauline L Balder, Romy M L Verhagen, Vinidhra Shankar, Barry Jutten, Pinak Samal, Timo Rademakers, Clemens A van Blitterswijk, Stefan Giselbrecht, Erik J Vrij

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dorian G LuijkxMERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0001-8670-1470
Pauline L Balder *MERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0009-0009-8766-5059
Romy M L Verhagen *MERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.
Vinidhra Shankar *MERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0003-1976-9023
Barry JuttenMERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.
Pinak SamalMERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0009-0008-1114-5447
Timo RademakersMERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0003-0286-418X
Clemens A van BlitterswijkMERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0003-2371-4615
Stefan Giselbrecht *MERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-1354-0167
Erik J Vrij *MERLN Institute for Technology-Inspired Regenerative Medicine, Department for Cell Biology-inspired Tissue Engineering, Maastricht University, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0003-0702-5609

Funding

Dutch Province of LimburgMaastrichts Universitair Medisch Centrum+ (MUMC+)
6 · The paper itself

Abstract

Understanding developmental toxicity demands capturing the full spectrum of morphological diversity, or morphospace, that defines early human embryogenesis. Traditional toxicity testing methods, relying on animal models or simplified 2D cell cultures, inherently overlook the nuanced interplay between distinct developmental stages and cell lineages. Addressing this gap, we present an innovative high-throughput screening approach leveraging three complementary 3D stem cell-based embryo models: preimplantation stage blastoids, and early postimplantation stage epiblast-like (EPICs) and amnion-like clusters (AMNICs). Cultured in thermoformed microwell arrays, these models were systematically exposed to a library of 27 widely used compounds. Automated image-based analyses allowed for precise quantification of morphotoxic effects. Key findings include the identification of compounds such as ascorbic acid and valproic acid (VPA), which demonstrated distinct and opposing effects across the different embryo models, highlighting developmental stage-specific sensitivities. This integrative platform underscores the essential role of complementary embryo models to achieve robust and human-relevant developmental toxicity assessment.

Indexed as

Embryo, MammalianEmbryonic DevelopmentModels, BiologicalToxicity TestsAnimalsBlastocystEmbryonic Stem CellsHumansMiceValproic AcidValproic Acidblastoidspostimplantation embryo modelsstem cell‐based embryo modelsthermoformed microwellstoxicity screening

Identifiers

PMID42657605
PMCPMC13586646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.